- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05457998
BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Tara Tang, BA
- Phone Number: 401-455-6402
- Email: memory@butler.org
Study Contact Backup
- Name: Philip Caffery, PhD
- Phone Number: 21004 401-455-6200
- Email: pcaffery@butler.org
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Recruiting
- Butler Hospital Memory and Aging Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals between the ages of 50 and 80 years old (inclusive)
- Score of 12 or above on the MoCA telephone
- Score of 27 or greater on the MMSE for individuals aged 50 to 64 years old or a score of 26 or greater for individuals aged 65 to 80 years old
- Participants in the 50-60 age range will additionally need to meet at least one of the following: (1) First degree family history of dementia with onset before age 75; (2) APOE e4 allele carrier; or (3) Prior elevated result on amyloid PET or amyloid CSF testing
- Conversationally fluent in English to the extent that an interpreter is not necessary for comprehension of the study information, procedures, and cognitive tests.
- If participants elect to participate in the optional disclosure procedure, they will be required to have an appropriate study partner who agrees to participate in the study and who is intellectually, visually, and auditory capable, and conversationally fluent in English to the extent that an interpreter is not necessary.
- Adequate visual and auditory acuity to allow neuropsychological testing.
- Participants must be willing and able to provide written informed consent.
Exclusion Criteria:
- Diagnosis of mild cognitive impairment or dementia
- History of significant brain injury or other known neurologic disease or insult, resulting in lasting cognitive sequelae that would confound the assessment and staging of potential neurodegenerative disease (e.g., Huntington's disease, Parkinson's disease, Parkinsonism due to multiple system atrophy (MSA), progressive supranuclear palsy (PSP), Shy Drager Syndrome (SDS) or other neuro-degenerative dementias, encephalitis or other brain infection, epilepsy or stroke with lasting impairment to cognitive function).
- Current serious or unstable systemic illness or organ failure that, in the PI's judgement, would make it difficult to participate in the study (e.g., such as terminal cancer, cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions ). History of cancer is acceptable with at least one year in remission with a good prognosis.
- Individuals with clinically significant depression, bipolar disorder, anxiety, or suicidal ideations within the past year as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM).
- A history of schizophrenia as defined by the most current version of the DSM.
- History within the past year of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM.
- Marijuana use is acceptable, but frequent users will be asked to abstain from use within 24 hours of any assessments.
- Refusing or unable to complete any study procedures.
- Currently enrolled in another study which involves clinical drug trial or other medical intervention.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sub-group 1: Optional Tau PET imaging sub-study
An optional tau PET imaging sub-study will be conducted in 70 subjects from the main study population who elect to participate. If enrolled in the optional tau PET imaging sub-study, participants will have three tau PET scans with [18F]RO-948: at baseline, 24 months, and 48 months. |
PET imaging of Tau aggregates
|
Main study population: Cognitively unimpaired individuals (50-80 y)
Participants will be enrolled based on a predetermined ratio of Alzheimer's Disease plasma and PET biomarker risk levels (e.g., as P-tau217 and amyloid PET). FOLLOW-UP FOR 4 YEARS: Cognitive testing, blood draws and retinal imaging will be conducted at baseline and 12 months. Cognitive testing and blood draws will be conducted at 24 months and 36 months. MRI and amyloid PET scans will be performed at screening/baseline and 24 months. An additional amyloid PET scan will be performed at 48 months. |
PET imaging of Abeta amyloid
Other Names:
|
Sub-group 2: Optional Tau PET tracer comparison sub-study
An optional tau PET tracer comparison sub-study will be conducted in 30 subjects from the main study population who elect to participate. Tau PET scans with 2 tracers ([18F]RO-948 and [18F]MK-6240) will be performed at baseline and 24 months. An additional Tau PET scan with [18F]RO-948 will be performed at 48 months. |
PET imaging of Tau aggregates
PET imaging of Tau aggregates
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of change in plasma biomarkers
Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Validate and assess longitudinal changes from baseline in plasma amyloid, phosphorylated tau (p-tau) and other fluid biomarkers (e.g., neurofilament light).
|
Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Rate of change in cerebral amyloid pathology
Time Frame: Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 5 years after baseline.
|
Longitudinal assessment of cerebral amyloidosis based on amyloid PET imaging.
|
Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 5 years after baseline.
|
Rate of change in Tau PET measures
Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Longitudinal assessment of cerebral tau accumulation based on tau PET imaging.
|
Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of cognitive decline as measured by traditional cognitive and behavioral assessments
Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Rate of cognitive decline as measured by digital cognitive assessments
Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Rate of change in retinal imaging metrics
Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Rate of change in psychological wellness as measured by the Geriatric Depression Scale
Time Frame: Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Time zero equals the baseline visit. All subjects will subsequently attend follow-up visits every year for 4 years after baseline.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen Salloway, MD,MS, Butler Hospital Memory and Aging Program
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Alzheimer Disease
- Cognitive Dysfunction
- Molecular Mechanisms of Pharmacological Action
- Radiopharmaceuticals
- Flutemetamol
Other Study ID Numbers
- 1745146
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on Flutemetamol F18 Injection
-
Skane University HospitalLund UniversityRecruitingAlzheimer Disease | Mild Cognitive Impairment | Mild DementiaSweden
-
Skane University HospitalLund UniversityRecruitingParkinson Disease | Dementia | Alzheimer Disease | Frontotemporal Degeneration | Mild Cognitive Impairment | Lewy Body Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Semantic Dementia | Parkinson-Dementia Syndrome | Progressive Nonfluent AphasiaSweden
-
GE HealthcareQuintiles, Inc.; Medpace, Inc.; i3 Statprobe; i3 ResearchCompletedMild Cognitive Impairment | Alzheimer's DiseaseUnited States
-
Eli Lilly and CompanyCompletedAlzheimer DiseaseUnited States, Japan, United Kingdom
-
Siemens Molecular ImagingTerminatedBreast CancerUnited States
-
GE HealthcareMedpace, Inc.; i3 StatprobeCompleted
-
Mayo ClinicCompletedAlzheimer's DiseaseUnited States
-
GE HealthcareCompletedMild Cognitive Impairment | Alzheimer's Disease
-
GE Healthcarei3 StatprobeTerminatedNormal Pressure HydrocephalusUnited States
-
GE Healthcarei3 StatprobeCompletedNormal Pressure HydrocephalusUnited States